| Qunhui Wang,Hua Zheng,Ying Hu,Baohua Lu,Fanbin Hu,Hongmei Zhang,Baolan Li. Icotinib, an EGFR-TKI, for the treatment of brain metastases in non-small cell lung cancer: a retrospective study. Oncol Transl Med, 2016, 2: 268-274. |
| Icotinib, an EGFR-TKI, for the treatment of brain metastases in non-small cell lung cancer: a retrospective study |
| Received:October 13, 2016 Revised:December 23, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:non-small cell lung cancer (NSCLC); brain metastases; icotinib; epidermal growth factor receptor (EGFR) |
| Author Name | Affiliation | E-mail | | Qunhui Wang | Department of Oncology,Beijing Chest Hospital,Capital Medical University | qunhui92@sina.com | | Hua Zheng* | Department of Oncology,Beijing Chest Hospital,Capital Medical University | zhenghua022@sina.com | | Ying Hu | Department of Oncology,Beijing Chest Hospital,Capital Medical University | | | Baohua Lu | Department of Oncology,Beijing Chest Hospital,Capital Medical University | | | Fanbin Hu | Department of Oncology,Beijing Chest Hospital,Capital Medical University | | | Hongmei Zhang | Department of Oncology,Beijing Chest Hospital,Capital Medical University | | | Baolan Li | Department of Oncology,Beijing Chest Hospital,Capital Medical University | |
|
| Hits: 7629 |
| Download times: 8150 |
| Abstract: |
| Objective Treatment of brain metastases from non-small cell lung cancer (NSCLC) is a challenge
because of the poor prognosis. Icotinib is a new type of oral epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) used in the treatment of advanced NSCLC. The aim of this study was to
evaluate the efficacy of icotinib in NSCLC patients with brain metastasis.
Methods This study reviewed records of 51 NSCLC patients with brain metastases who took icotinib 125
mg, 3 times a day. Response rate, progression free survival, and overall survival were analyzed. SPSS
software version 17.0 was used for univariate analysis, and Cox regression analysis to analyze factors
affecting survival.
Results Thirty-six cases had partial response, 6 cases had stable disease, and 10 cases had progressive
disease. In 31 cases, EGFR gene mutation test were performed. EGFR was mutated in 26 cases and was
with wild-type in 5 cases. In patients with EGFR mutations, 23 patients responded to icotinib [the disease
control rate (DCR) was 88.5%], significantly higher than in patients with wild-type EGFR (1 patient, DCR
20%) (P = 0.005). The overall median progression-free survival (PFS) was 7.6 months. PFS was longer
in the patients with EGFR mutations than in those with wild type EGFR (7.8 months vs 1.2 months, P =
0.03). The overall median overall survival (OS) time was 10.7 months. OS was longer in patients with
EGFR mutations than in those with wild type EGFR (15.1 months vs 6.7 months, P = 0.003). The main
side effects of the treatment were skin rash and diarrhea; no stage 3 or 4 toxic effects occurred. Univariate
analysis demonstrated that OS was related to sex, Eastern Cooperative Oncology Group performance
status (ECOG PS), smoking history, and EGFR mutation. Multivariate analysis showed that OS was
independently related to sex, ECOG PS, and EGFR mutations.
Conclusion Icotinib has a favorable effect on NSCLC patients with brain metastases harboring EGFR
mutations. Icotinib can be a new choice of treatment for brain metastases in patients with NSCLC harboring
EGFR mutations. |
| Close |
|
|
|